Clinical Convergence®: Changing Perspectives—Fine Tuning Treatment for the Relapsed Refractory Patient with Chronic Myeloid Leukemia

Program Overview

This Clinical Convergence ® activity addresses new developments in the treatment of relapsed/refractory CML with a focus on appropriate therapeutic decision making and monitoring in the second- and third-line setting. The program features a clinical case vignette to engage the learner and facilitate acquisition and integration of new skills and behaviors, as well as a patient encounter to provide unique perspectives on aspects of treatment selection, adherence, monitoring requirements, and adverse event management. A non-certified practice aid is included as a resource for provider-patient discussions on potential side effects.

Credit Expired
0.75 CE Credit(s)
Expires: June 14, 2022

Target Audience

This activity is intended for medical oncologists, hematologists, NPs, PAs, nurses, and other HCPs engaged in the care of patients with chronic myeloid leukemia (CML).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Employ key data on tyrosine kinase inhibitors (TKIs) when treating and monitoring patients with relapsed or refractory CML
  • Select appropriate therapy for patients with CML refractory to 2nd generation agents
  • Integrate strategies to monitor and manage potential adverse effects, such as cardiotoxicity, that may result in cross-intolerance to TKIs in patients with CML

Activity Faculty


Jorge Cortes, MD (Course Director)

Director, Georgia Cancer Center
Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer
Augusta, GA


Mahran Shoukier, MD

Hematology/Oncology Fellow
Section of Hematology/Oncology, Department of Medicine
Georgia Cancer Center at Augusta University
Augusta, GA

Relapsed or Refractory Chronic-Phase: CHRONIC MYELOID LEUKEMIA (CML)

Supporter Statement

Provider Statement

Disclosure of Financial Relationships


Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources